Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an announcement.
Prescient Therapeutics Limited announced a change in the director’s interest, with Dr. Gavin Shepherd acquiring additional shares through an on-market trade. This acquisition reflects a modest increase in Dr. Shepherd’s indirect holdings, potentially signaling confidence in the company’s future prospects and stability in its leadership.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in creating targeted and personalized treatment options to improve patient outcomes in oncology.
YTD Price Performance: -20.0%
Average Trading Volume: 652,016
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$32.21M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.